AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01290133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW597599
Description: Single dose IV infusion
Study NCT01290133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose IV infusion
Study NCT03614442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: slopped shoulder implant
Description: different implant design to enhance soft and hard tissue outcome
Study NCT01429688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anplag
Description: Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
Study NCT03614442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: slopped shoulder implant
Description: different implant design to enhance soft and hard tissue outcome
Study NCT00353652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study #1: spironolactone (SP), titrated dose
Description: Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.
Study NCT00353652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 chlorthalidone (CTD), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
Study NCT00353652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 spironolactone (SP), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
Study NCT00353652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study# 2 irbsesartan (IR), fixed dose
Description: Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
Study NCT03294681 — intervention group
Intervention type: DEVICE
Intervention: Objective measures with CSEP
Description: Objective measures to be conducted with Custom SoundTM EP 5 software and the CP900 series sound processor in CI532 and CI512 Cochlear Implant recipients
Study NCT00778427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride 1000 mg tablets
Study NCT00778427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin hydrochloride 1000 mg tablets
Study NCT02172794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Study NCT02172794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tiotropium
Study NCT02172794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Study NCT02172794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to salmeterol
Study NCT02536170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
Study NCT02536170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine Loading Dose
Description: One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
Study NCT03156114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Day 1 of 3 week cycle
Study NCT03156114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Day 1 of 3 week cycle
Study NCT03700177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.
Study NCT03700177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).
Study NCT03700177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Injection [Naropin]
Description: 30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
Study NCT03700177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine Injection [Naropin]
Description: 30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
Study NCT02536170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
Study NCT02969434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep assessment tools
Description: Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
Study NCT04123717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ibuprofen
Description: The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
Study NCT02720016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT-Home Based (CBCT-HB)
Description: Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
Study NCT03589274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-FS-CBT
Description: 12 manual-guided sessions of I-FS-CBT
Study NCT03589274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G-FS-CBT
Description: 12 manual-guided sessions of G-FS-CBT
Study NCT03159182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure garment and silicone insert
Description: Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.
Study NCT03159182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure garment
Description: Custom made fabric pressure garment
Study NCT02720016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBCT-Office Based (CBCT-OB)
Description: Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
Study NCT02720016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PTSD Family Education (PFE)
Description: Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
Study NCT02416362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration at 30 Hz
Description: During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.
Study NCT02416362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration at 50 Hz
Description: During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
Study NCT03355937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sperm Chip
Description: Sperm selection using by conventional or with sperm chip
Study NCT03355937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sperm Chip
Description: Sperm selection using by conventional or with sperm chip
Study NCT01959737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin-to.skin-contact
Description: Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
Study NCT01189435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
Study NCT01770873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take Charge 2
Description: Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
Study NCT01948284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: half-maximal pressure
Description: the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).
Study NCT01948284 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maximal pressure
Description: The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
Study NCT01948284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suction Unit
Study NCT02191709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan syrup
Study NCT02191709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan soft pastilles
Study NCT00511524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW842166X
Description: GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
Study NCT00511524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [carbonyl-^11C]GW842166
Description: \[carbonyl-\^11C\]GW842166 will b available as Intravenous solution.
Study NCT01679080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: antiresorptive and calcium and vitamin D
Study NCT01679080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: anabolic and calcium and vitamin D
Study NCT01679080 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No active treatment
Description: Calcium and vitamin D
Study NCT04202861 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In vitro antibiotic combination testing (iACT)
Description: CRGNB isolates from the index culture will be transported to the Pharmacy Research Lab,SGH for iACT testing. iACT results will be sent to the physicians and ID specialist managing the patient once completed. A subset of results will be published in the iACT report. Participants enrolled into the intervention arm -should ideally be kept on an iACT combination for the required treatment period. However during the treatment period, the treating doctor-in-charge and or the consulting infectious disease doctor may wish to continuing iACT antibiotic combination therapy or modifying the combinations based on their best clinical judgement for the patient.
Study NCT01434888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative free tafluprost 0.0015% eye drops
Description: Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
Study NCT01434888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative free timolol 0.5% eye drops
Description: Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
Study NCT03643081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the camera Fluobeam
Description: Use of the camera Fluobeam to localize, visualize the parathyroid glands during a parathyroidectomy.
Study NCT01434888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops
Description: Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
Study NCT00383422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arzoxifene
Description: 20 mg, oral, tablet, once a day for 52 weeks
Study NCT00383422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Description: 60 mg, oral, tablet, once a day for 52 weeks
Study NCT04088851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: On Metformin
Description: Oral intake of Metformin (1 g / day) for 2 weeks
Study NCT04088851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Off Metformin
Description: No oral intake of Metformin (1 g / day) for 2 weeks
Study NCT03242083 — intervention group
Intervention type: OTHER
Intervention: quality of life questionnaire
Description: quality of life questionnaire
Study NCT02753829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiovascular rehabilitation program using Kinect of Xbox
Description: Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
Study NCT02753829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiovascular rehabilitation program using paper manual
Description: Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
Study NCT02753829 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational component
Description: It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
Study NCT03970395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh)
Description: The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.
Study NCT03970395 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light Touch Therapy (LTT)
Description: The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.
Study NCT03970395 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Repositioning therapy
Description: It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed.
Study NCT03970395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repositioning therapy
Description: It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed.
Study NCT03768791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCS is switched off
Description: Spinal cord stimulator is switched off for 12 hours
Study NCT03768791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCS is switched on
Description: Spinal cord stimulator is on
Study NCT01276457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus 0.25 and 0.75 mg tablets
Description: The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
Study NCT01276457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 0.25 and 0.75 mg tablets
Description: The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
Study NCT01276457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine very low dose (150-300 ng/mL) microemulsion
Description: The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
Study NCT01276457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine low dose (350-500 ng/mL) microemulsion
Description: The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
Study NCT00825383 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Fiber and Moderate Fiber Diets
Description: Dietary
Study NCT00608530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy-Psychologist-Delivered
Description: Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist
Study NCT00608530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy-Psychologist-Delivered
Description: Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
Study NCT02089698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-flared
Description: Mini-flared Kelman tip
Study NCT02089698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reversed tip
Description: Reversed Kelman tip
Study NCT00977223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant/placebo
Description: Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
Study NCT00242606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: titrate to 200mg over 10 weeks and maintained until end of week 26
Study NCT00242606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: titrate to 2000mg/day over 22 days, maintain until the end of week 26
Study NCT00608530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy Nurse-Delivered
Description: Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse
Study NCT00608530 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy-Nurse-Delivered
Description: Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
Study NCT03006055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells
Study NCT03498573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tunneling surgical technique
Description: sticky bone prepared by centrifuge patient blood and mixing with xinograft